vendredi 6 septembre 2019

Onco Actu du 6 septembre 2019


3.1.1 PRÉVENTION - TABAC - E-CIGS



Vitamin E Suspected In Serious Lung Problems Among People Who Vaped Cannabis [NPR]











Contaminant found in vaping products linked to deadly lung illnesses, state and federal labs show [Washington Post]











4.10 DÉP., DIAG. & PRONO. - POUMON



Screenings for lung cancer can point to other smoking-related conditions [UPI]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Large-Scale Multigene Panel Study of Hereditary Cancer Risk Refines Gene Associations [Genome Web]











4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Fewer women do bowel screening test [University of Glasgow]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Analysis of cervical cancer and abnormality outcomes in an era of cervical screening and HPV vaccination in Australia [AIHW]










5. TRAITEMENTS



Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect' [Reuters]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Using MicroRNA to Starve a Tumor? [NIH Director's Blog]











5.12 IMMUNOTHÉRAPIES



Researchers Characterize Lung Inflammation Associated With Some Cancer Immnunotherapy [Johns Hopkins]










5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Bristol-Myers Squibb's Opdivo fails 3rd straight test in tough-to-treat brain cancer [Fierce Pharma]










Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme [BMS]











Strike three: Bristol-Myers’ third I/O shot at glioblastoma misses as Opdivo flops yet again on key endpoint [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer [Roche]











European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer [Roche]











5.2 PHARMA



Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer [Novartis]











Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful [Reuters]











5.2.1 PHARMA - PARTENARIATS



Theragnostics Signs Agreement With AstraZeneca [Theragnostics]











5.2.3 PHARMA - ÉCONOMIE



How much has the cancer R&D frenzy translated into drug approvals? A lot [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Ned Sharpless in final running for FDA commish with MD Anderson exec and Harvard prof — reports [EndPoints]











6.1 OBSERVATION



PTSD linked to increased risk of ovarian cancer [Harvard]











Global Analysis Finds Early Onset Colorectal Cancer Now Rising in Many High-Income Countries [ACS]